SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-120391
Filing Date
2022-11-18
Accepted
2022-11-18 17:19:01
Documents
14
Period of Report
2022-11-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2230330d2_8k.htm   iXBRL 8-K 33864
2 EXHIBIT 1.1 tm2230330d2_ex1-1.htm EX-1.1 228714
3 EXHIBIT 5.1 tm2230330d2_ex5-1.htm EX-5.1 6891
  Complete submission text file 0001104659-22-120391.txt   503887

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA iova-20221118.xsd EX-101.SCH 3021
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE iova-20221118_lab.xml EX-101.LAB 34476
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE iova-20221118_pre.xml EX-101.PRE 22587
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2230330d2_8k_htm.xml XML 3624
Mailing Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070 6502607120
IOVANCE BIOTHERAPEUTICS, INC. (Filer) CIK: 0001425205 (see all company filings)

IRS No.: 753254381 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36860 | Film No.: 221402854
SIC: 2836 Biological Products, (No Diagnostic Substances)